LO-021 Interim safety and efficacy of subcutaneous (s.c.) dose ianalumab (VAY736; anti-BAFF-R mAb) administered monthly over 28 weeks in patients with systemic lupus erythematosus (SLE)

Shin-Seok Lee, Stanislav Ignatenko, Alexander Gordienko, Josefina Hernandez, Nancy Levin, Pongthorn Narongroeknawin, Katarzyna Romanowska-Prochnicka, Nan Shen, Hanna Ciferska, Masanari Kodera, Cheng-Chung Wei, Piotr Leszczynski, Joung Liang Lan, Rafal Wojciechowski, Tunde Tarr, Elena Vishneva, Yi Hsing Chen, Yuko Kaneko, Stephanie Finzel, Alberta Hoi, Masato Okada, Ajchara Koolvisoot, Lie Dai, Hiroshi Kaneko, Bernadette Rojkovich, Lingyun Sun, Eugeny Zotkin, Berta Paula magallares, Tirtha Sengupta, Carole Sips, Stephan Oliver

Open source

DOI: 10.1136/lupus-2023-kcr.21
Published: 2023-07
Container: Oral Presentation
Publisher: Lupus Foundation of America
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/lupus-2023-kcr.21,
  title = {LO-021 Interim safety and efficacy of subcutaneous (s.c.) dose ianalumab (VAY736; anti-BAFF-R mAb) administered monthly over 28 weeks in patients with systemic lupus erythematosus (SLE)},
  author = {Shin-Seok Lee and Stanislav Ignatenko and Alexander Gordienko and Josefina Hernandez and Nancy Levin and Pongthorn Narongroeknawin and Katarzyna Romanowska-Prochnicka and Nan Shen and Hanna Ciferska and Masanari Kodera and Cheng-Chung Wei and Piotr Leszczynski and Joung Liang Lan and Rafal Wojciechowski and Tunde Tarr and Elena Vishneva and Yi Hsing Chen and Yuko Kaneko and Stephanie Finzel and Alberta Hoi and Masato Okada and Ajchara Koolvisoot and Lie Dai and Hiroshi Kaneko and Bernadette Rojkovich and Lingyun Sun and Eugeny Zotkin and Berta Paula magallares and Tirtha Sengupta and Carole Sips and Stephan Oliver},
  year = {2023},
  journal = {Oral Presentation},
  doi = {10.1136/lupus-2023-kcr.21},
  url = {https://doi.org/10.1136/lupus-2023-kcr.21}
}

RIS

TY  - JOUR
TI  - LO-021 Interim safety and efficacy of subcutaneous (s.c.) dose ianalumab (VAY736; anti-BAFF-R mAb) administered monthly over 28 weeks in patients with systemic lupus erythematosus (SLE)
AU  - Shin-Seok Lee
AU  - Stanislav Ignatenko
AU  - Alexander Gordienko
AU  - Josefina Hernandez
AU  - Nancy Levin
AU  - Pongthorn Narongroeknawin
AU  - Katarzyna Romanowska-Prochnicka
AU  - Nan Shen
AU  - Hanna Ciferska
AU  - Masanari Kodera
AU  - Cheng-Chung Wei
AU  - Piotr Leszczynski
AU  - Joung Liang Lan
AU  - Rafal Wojciechowski
AU  - Tunde Tarr
AU  - Elena Vishneva
AU  - Yi Hsing Chen
AU  - Yuko Kaneko
AU  - Stephanie Finzel
AU  - Alberta Hoi
AU  - Masato Okada
AU  - Ajchara Koolvisoot
AU  - Lie Dai
AU  - Hiroshi Kaneko
AU  - Bernadette Rojkovich
AU  - Lingyun Sun
AU  - Eugeny Zotkin
AU  - Berta Paula magallares
AU  - Tirtha Sengupta
AU  - Carole Sips
AU  - Stephan Oliver
PY  - 2023
JO  - Oral Presentation
DO  - 10.1136/lupus-2023-kcr.21
UR  - https://doi.org/10.1136/lupus-2023-kcr.21
ER  -

APA

Lee, S., Ignatenko, S., Gordienko, A., Hernandez, J., Levin, N., Narongroeknawin, P., Romanowska-Prochnicka, K., Shen, N., Ciferska, H., Kodera, M., Wei, C., Leszczynski, P., Lan, J. L., Wojciechowski, R., Tarr, T., Vishneva, E., Chen, Y. H., Kaneko, Y., Finzel, S., Hoi, A., Okada, M., Koolvisoot, A., Dai, L., Kaneko, H., Rojkovich, B., Sun, L., Zotkin, E., magallares, B. P., Sengupta, T., Sips, C., & Oliver, S. (2023). LO-021 Interim safety and efficacy of subcutaneous (s.c.) dose ianalumab (VAY736; anti-BAFF-R mAb) administered monthly over 28 weeks in patients with systemic lupus erythematosus (SLE). Oral Presentation. https://doi.org/10.1136/lupus-2023-kcr.21

Source records

crossref · retrieved 2026-09-26T06:27:54.588Z